What is Pf-08032562 used for?

Pf-08032562 is indicated for Multiple Myeloma, Lymphoma, Leukemia.

Who makes Pf-08032562?

Pf-08032562 is developed by Pfizer Inc..

What development phase is Pf-08032562 in?

Pf-08032562 is FDA-approved (marketed).

What is the generic name of Pf-08032562?

pf-08032562 is the generic (nonproprietary) name of Pf-08032562.

Last reviewed 2026-04-20 · How we verify

Pf-08032562 (pf-08032562)

Pfizer Inc. · FDA-approved active Quality 25/100

At a glance

Generic name	pf-08032562
Sponsor	Pfizer Inc.
Drug class	unknown
Target	unknown
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

Multiple Myeloma
Lymphoma
Leukemia

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Aspirin
Pentobarbital
Phenobarbital
Rivaroxaban
Apixaban
Dabigatran
Clopidogrel
Ticagrelor
Prasugrel
Cilostazol
Dipyridamole

Key clinical trials

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pf-08032562 CI brief — competitive landscape report
Pf-08032562 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI